Speakers
Agata Nyga
Alex Ide
Esther Wershof
Peter Hamley
Therapeutics and discovery track
Come and hear from 5 of the most exciting organisations working in this space as they walk us through their achievements, and how they will change the landscape. Vote for the one you think will have the greatest impact to give them a chance to speak again in the final plenary session.
Dr Agata Nyga is co-founder and CEO of Mechanome Bio, a Cambridge-based TechBio company applying AI to map and drug mechanical layer of disease - mechanome. At Mechanome, she combines spatial multi-omics, mechanomics and advanced disease model to turn mechano-associated pathways into therapeutic opportunities. She has over 15 years of experience driving innovative science and acts as a policy advisor for non-for-profit organisations.
Dr Esther Wershof is a Senior Scientist in the Machine Learning group at Altos Labs, where she architects AI-driven platforms to model cell rejuvenation and reverse disease. Operating at the cutting edge of Lab-in-the-Loop engineering , she recently co-led the global team that won the prestigious $100k ARC Virtual Cell Challenge at NeurIPS 2025 and launched a pioneering open-source benchmarking platform that is setting new standards for perturbation prediction.
Peter Hamley is founder and CEO of Scripta Therapeutics, a new techbio based in Oxford. Scripta is flipping the script on drug discovery by implementing a novel approach involving multiomics, imaging, computer vision and target identification to modulate transcription factors. The output is a portfolio of disease modifying therapeutics for neurodegeneration.
Hugely experienced in the pharma and biotech world, Peter was previously CSO at Samsara Therapeutics, building a team at the intersection of neuroscience and ageing biology. While at Sanofi, he led global departments in drug discovery and business development, advancing multiple programs across numerous disease areas. His earlier roles include positions at AstraZeneca and the University of Pennsylvania.
He holds a PhD from the University of Cambridge, an MBA from the University of Bath, and a BSc in Chemistry from Imperial College London. He has authored over 60 patents and publications.
Timothé Cynober is a Head of Business Development & Licensing at Whitelab Genomics and Chairman of the Techbio France initiative. Prior to joining WLG, Timothé held various positions in open innovation, technology transfer, and licensing at Institut Curie, where he worked as a Business Manager for four years, and at Novartis France, where he served as an Open Innovation Manager for two years. Timothé also has experience in regulatory affairs consulting, having worked at Voisin Consulting Life Science. He holds a Doctorate in Pharmacy and a Master’s degree in Biotechnology and Innovative Therapies from Université Paris-Saclay.